A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Sponsor: Bavarian Nordic
A PHASE3 clinical study on Chikungunya Virus, this trial is completed. The trial is conducted by Bavarian Nordic and has accumulated 11 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2023 — Jan 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
May 2023 — Aug 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2022 — May 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — May 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
First recorded
Sep 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bavarian Nordic
- Emergent BioSolutions
For direct contact, visit the study record on ClinicalTrials.gov .